Jacobs Levy Equity Management’s Ocular Therapeutix OCUL Stock Holding History

Jacobs Levy Equity Management’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.3M	Sell	335,666 -134,363	-29%	-$1.22M	0.01%	499
2026 Q1	$3.98M	Buy	470,029 +176,766	+60%	+$1.68M	0.02%	464
2025 Q4	$3.56M	Buy	+293,263	New	+$3.56M	0.01%	475
2022 Q4	–	Sell	-100,809	Closed	-$418K	–	1007
2022 Q3	$418K	Buy	+100,809	New	+$508K	﹤0.01%	846
2022 Q1	–	Sell	-59,810	Closed	-$417K	–	1055
2021 Q4	$417K	Buy	+59,810	New	+$464K	﹤0.01%	855

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jacobs Levy Equity Management's OCUL Position: Q2 2026 in Review

Jacobs Levy Equity Management reduced its Ocular Therapeutix (OCUL) stake by 29% in Q2 2026, selling an estimated $1.22M and leaving 335,666 shares worth $3.3M. The position accounts for 0.01% of the portfolio, ranked #499.

Jacobs Levy Equity Management first reported a position in OCUL in Q4 2021 and has held it in 5 quarters since. The position peaked at $3.98M in Q1 2026. 263 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

Jacobs Levy Equity Management held 335,666 shares of Ocular Therapeutix worth $3.3M as of Q2 2026.
Jacobs Levy Equity Management sold 134,363 Ocular Therapeutix shares in Q2 2026, an estimated $1.22M.
Ocular Therapeutix made up 0.01% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #499 holding.
Jacobs Levy Equity Management first reported a position in Ocular Therapeutix in Q4 2021 and has held it in 5 quarters since.
Jacobs Levy Equity Management's Ocular Therapeutix position peaked at $3.98M in Q1 2026.
263 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.